Cure My Disease

Don't miss your cure!

 Log in / Sign up

Metabolic MRI could spot prostate cancer without a needle

NCT ID NCT04698564

Terminated Diagnosis Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study tests a new type of MRI scan that uses a special contrast agent called hyperpolarized pyruvate to see how prostate cells use energy. The goal is to safely distinguish cancerous from normal tissue in men with suspected or known prostate cancer. Participants receive the injection and undergo metabolic MRI before their planned biopsy or surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Hyperpolarized 13C-Pyruvate injection, a contrast agent for metabolic MRI
What this could lead to
If successful, this imaging technique could provide a non-invasive way to detect and risk-stratify prostate cancer, potentially reducing unnecessary biopsies.
What could go wrong
This is a very small pilot study with only 4 participants, so results may not generalize. The scan's accuracy compared to standard biopsy is still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

  • University of Maryland Medical Center

    Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.